OTCMKTS:HYPMY Hypermarcas (HYPMY) Stock Price, News & Analysis $4.24 +0.09 (+2.17%) As of 09/15/2025 02:49 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartDividendEarningsHeadlinesSEC FilingsShort InterestBuy This Stock About Hypermarcas Stock (OTCMKTS:HYPMY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Hypermarcas alerts:Sign Up Key Stats Today's Range$4.05▼$4.4450-Day Range$4.01▼$5.0252-Week Range$2.64▼$5.36Volume5,534 shsAverage Volume19,255 shsMarket Capitalization$2.69 billionP/E Ratio20.19Dividend Yield2.83%Price TargetN/AConsensus RatingStrong Buy Company Overview Hypermarcas S.A. is a Brazil-based consumer health and pharmaceutical company whose shares trade over the counter in the United States under the symbol HYPMY. Founded in the early 2000s and headquartered in Rio de Janeiro, the company operates as a holding group for a broad portfolio of branded products in the healthcare and personal care sectors. Through its various subsidiaries, Hypermarcas develops, manufactures and markets prescription and over-the-counter medications, alongside personal care, baby care, home care and nutritional supplement products. Its pharmaceutical lineup includes analgesics, anti-inflammatories, vitamins and dermatological preparations, while its consumer goods segment encompasses shampoos, soaps, lotions and oral hygiene items under multiple local brands. Primarily focused on the domestic Brazilian market, Hypermarcas has also extended its reach into other Latin American countries via export partnerships and regional distributors. Over the years, the company has grown through acquisitions of smaller domestic drugmakers and consolidation of well-known local brands. Detailed executive leadership information is not widely available in public sources.AI Generated. May Contain Errors. Read More Receive HYPMY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hypermarcas and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HYPMY Stock News HeadlinesBrazil's Hypera announces new majority stakeholder groupJuly 7, 2025 | reuters.comHypera S.A. (HYPMY) Stock Price, Quote, News & Analysis - Seeking AlphaJune 29, 2025 | seekingalpha.comTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes. | Porter & Company (Ad)Hypera S.A. credit rating downgraded due to increased leverageApril 9, 2025 | investing.comHypera SA (HYPMY) Q4 2024 Earnings Call Highlights: Navigating Growth and ChallengesMarch 24, 2025 | finance.yahoo.comHypera S.A. Reports 2024 Financial PerformanceMarch 21, 2025 | tipranks.comHypera S.A. (HYPMY) Q4 2024 Earnings Call TranscriptMarch 21, 2025 | seekingalpha.comHypera: Short-Term Pain For Long-Term GainNovember 26, 2024 | seekingalpha.comSee More Headlines HYPMY Stock Analysis - Frequently Asked Questions How have HYPMY shares performed this year? Hypermarcas' stock was trading at $3.06 at the beginning of 2025. Since then, HYPMY shares have increased by 38.6% and is now trading at $4.24. How were Hypermarcas' earnings last quarter? Hypermarcas (OTCMKTS:HYPMY) announced its quarterly earnings results on Wednesday, August, 6th. The company reported $0.12 earnings per share for the quarter. Hypermarcas had a net margin of 11.28% and a trailing twelve-month return on equity of 6.19%. How do I buy shares of Hypermarcas? Shares of HYPMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/06/2025Today9/15/2025Next Earnings (Estimated)10/29/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - DRUGS Sub-IndustryN/A Current SymbolOTCMKTS:HYPMY CIK1486749 Webwww.hyperapharma.com.br Phone55-11-3627-4206FaxN/AEmployees10,481Year FoundedN/AProfitability EPS (Trailing Twelve Months)$0.21 Trailing P/E Ratio20.19 Forward P/E RatioN/A P/E GrowthN/ANet Income$248.62 million Net Margins11.28% Pretax Margin2.82% Return on Equity6.19% Return on Assets2.98% Debt Debt-to-Equity Ratio0.63 Current Ratio1.26 Quick Ratio0.80 Sales & Book Value Annual Sales$1.38 billion Price / Sales1.95 Cash Flow$0.48 per share Price / Cash Flow8.78 Book Value$3.54 per share Price / Book1.20Miscellaneous Outstanding Shares633,420,000Free FloatN/AMarket Cap$2.69 billion OptionableNot Optionable Beta0.86 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (OTCMKTS:HYPMY) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis Coin Could Explode, and it’s Hiding in Plain Sight!The #1 coin with skyrocket potential right now... Sometimes the biggest opportunities are hiding in plain s...Crypto 101 Media | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredDalio’s $319 Million Gold BetA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored“Godfather of AI’s” dire warningAI pioneer Geoffrey Hinton warns the technology could create massive unemployment and widen inequality, but Po...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hypermarcas Please log in to your account or sign up in order to add this asset to your watchlist. Share Hypermarcas With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.